daunorubicin has been researched along with linagliptin in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Dranchak, PK; Huang, R; Inglese, J; Lamy, L; Oliphant, E; Queme, B; Tao, D; Wang, Y; Xia, M | 1 |
| Doka, G; Klimas, J; Krenek, P; Marusakova, M; Pivackova, L; Srankova, J; Veteskova, J | 1 |
2 other study(ies) available for daunorubicin and linagliptin
| Article | Year |
|---|---|
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Topics: Animals; Caenorhabditis elegans; Drug Discovery; High-Throughput Screening Assays; Humans; Proteomics; Small Molecule Libraries | 2023 |
Pegfilgrastim and linagliptin potentiate chemoattraction of Ccr2 and Cd44 stem cells accompanied by alterations of cardiac Hgf, Igf-1 and Mcp-1 in daunorubicin cardiomyopathy.
Topics: Animals; Biomarkers; Cardiomyopathies; Cell Movement; Chemokine CCL2; Cytokines; Daunorubicin; Filgrastim; Heart; Hepatocyte Growth Factor; Hyaluronan Receptors; Insulin-Like Growth Factor I; Kaplan-Meier Estimate; Linagliptin; Male; Myocardium; Oxidative Stress; Polyethylene Glycols; Rats; Rats, Wistar; Receptors, CCR2; Stem Cells | 2019 |